Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Syntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025
Posted: December 21, 2024 at 2:54 am
NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce its participation in Biotech Showcase 2025, taking place January 13–15, 2025, in San Francisco.
Read the original here:
Syntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025
Posted in Global News Feed
Comments Off on Syntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
Posted: December 21, 2024 at 2:54 am
BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.
Posted in Global News Feed
Comments Off on Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29,…
Posted: December 21, 2024 at 2:54 am
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Posted in Global News Feed
Comments Off on Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29,…
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Posted: December 21, 2024 at 2:53 am
Confirms Previously Disclosed and Anticipated FDA Decision Confirms Previously Disclosed and Anticipated FDA Decision
Read the original:
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Posted in Global News Feed
Comments Off on Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
Posted: December 21, 2024 at 2:53 am
MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
Excerpt from:
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
Posted in Global News Feed
Comments Off on Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
Posted: December 21, 2024 at 2:53 am
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce its financial and operational results for the year ended August 31, 2024, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company’s full set of consolidated audited financial statements for the years ended August 31, 2024 and 2023 and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.
Read the original here:
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
Posted in Global News Feed
Comments Off on PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Posted: December 7, 2024 at 2:50 am
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
Originally posted here:
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Posted in Global News Feed
Comments Off on Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from…
Posted: December 7, 2024 at 2:50 am
Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ?10g/dL following treatment with eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the average Hb level improved versus baseline1.
Continue reading here:
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from...
Posted in Global News Feed
Comments Off on New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from…
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Posted: December 7, 2024 at 2:50 am
Availability of the revised financial statements for Sanofi excluding Opella
See the original post:
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Posted in Global News Feed
Comments Off on Press Release: Availability of the revised financial statements for Sanofi excluding Opella
